MedPath
HSA Product

GAVISCON DOUBLE ACTION LIQUID, SUSPENSION

Product approved by Health Sciences Authority (SG)

Basic Information

GAVISCON DOUBLE ACTION LIQUID, SUSPENSION

SUSPENSION

Regulatory Information

SIN14016P

September 19, 2011

General Sale List

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XA02AD01

Company Information

RECKITT BENCKISER (SINGAPORE) PTE LTD

RECKITT BENCKISER (SINGAPORE) PTE LTD

Active Ingredients

SODIUM BICARBONATE

Strength: 213MG/10ML

CALCIUM CARBONATE

Strength: 325MG/10ML

SODIUM ALGINATE

Strength: 500MG/10ML

Detailed Information

Contraindications

**Before taking this product.** Each 20ml dose contains 11.06 mmol sodium and 6.5 mmol calcium. If you have been advised a diet restricted in any of these please ask your doctor before taking this product. Do not take if you know you are allergic to any of the ingredients as very rarely difficulty in breathing and skin rashes have occurred. Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). Consult your doctor if you experience these or any other side effects.

Indication Information

Gaviscon Double Action Liquid brings relief from the pain and discomfort of heartburn and acid indigestion. It gets to work in two different ways: 1. neutralising excess stomach acid to relieve pain and discomfort. 2. forming a protective barrier over the stomach contents to soothe the burning pain in your chest.

© Copyright 2025. All Rights Reserved by MedPath